SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.39+1.0%Nov 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (38)1/27/2016 9:03:55 PM
From: tuck1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (2) of 294
 
Bromodomain inhibition in oncology is the bailiwick of several players. I mentioned Merck. Others include:

Constellation CPI-0610

GSK GSK525762

Roche TEN-010 this comes from the Bradner lab at Dana Farber where some pioneering work in this area has been done.

All these are in early stage trials with readouts in a year or so. DLTs to date include thrombocytopenia and diarrhea. The Merck compound managed a couple of complete remissions.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News